Moderna (MRNA) has announced a setback in the anticipated approval of its RSV vaccine. The biopharmaceutical company says that the US Food and Drug Administration (FDA) has postponed the decision to approve the vaccine until the end of May due to administrative constraints.

Yahoo Finance's health reporter Anjalee Khemlani breaks down the details.

For more expert insight and the latest market action, click here to watch this full episode of Catalysts.

This post was written by Angel Smith

Video Transcript

Moderna shares after, after the company announcing that the FDA has delayed the approval of its RSV vaccine to the end of May.

Yahoo finances, Angeli Kelani joining us now with the latest on.

That's right guys.

So uh the FDA let Moderna know that even though they were supposed to have a decision by this weekend for that RSV vaccine, they're going to have to delay it due to administrative constraints until the end of May.

Now this doesn't fully throw the approval process off track.

The CDC is still on, on track to get to their portion of the approval process in June.

So it doesn't totally throw off the timeline, but it does put a little wrench in the overall timeline for Moderna which has been waiting to get this product to market to make it the second product that it gets revenues out of.

So that is the only concern for this right now while it doesn't throw off the entire process.

Uh it does put sort of a, a little little tiny dark cloud over Moderna for the day.

All right.

Um Thanks so much for breaking down that story for us and certainly a trade here that uh investors should continue to watch.